A collection of essays examining the current status of the therapeutic potential of hallucinogenic substances, exploring how the drugs can be used to effectively treat a wide range of conditions.
This handbook reviews promising applications of psychedelics in treatment of such challenging psychiatric problems as posttraumatic stress disorder, major depression, substance use disorders, and end-of-life anxiety. Experts from multiple disciplines synthesize current knowledge on psilocybin, MDMA, ketamine, and other medical hallucinogens. The volume comprehensively examines these substances' neurobiological mechanisms, clinical effects, therapeutic potential, risks, and anthropological and historical contexts. Coverage ranges from basic science to practical clinical considerations, including patient screening and selection, dosages and routes of administration, how psychedelic-assisted sessions are structured and conducted, and management of adverse reactions.
Explores the potential of psychedelics as medicine and the intersections of politics, science, and psychedelics • Explores the tumultuous history of psychedelic research, the efforts to restore psychedelic therapies, and the links between psychiatric drugs and mental illness • Offers non-technical summaries of the most recent, double-blind, placebo-controlled studies with MDMA, psilocybin, LSD, and ayahuasca • Includes the work of Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker Embracing the revival of psychedelic research and the discovery of new therapeutic uses, clinical psychologist Dr. Richard Louis Miller discusses what is happening today in psychedelic medicine--and what will happen in the future--with top researchers and thinkers in this field, including Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker. Dr. Miller and his contributors cover the tumultuous history of early psychedelic research brought to a halt 50 years ago by the U.S. government as well as offering non-technical summaries of the most recent studies with MDMA, psilocybin, LSD, and ayahuasca. They explore the biochemistry of consciousness and the use of psychedelics for self-discovery and healing. They discuss the use of psilocybin for releasing fear in the terminally ill and the potential for MDMA-assisted psychotherapy in the treatment of PTSD. They examine Dr. Charles Grob’s research on the indigenous use and therapeutic properties of ayahuasca and Dr. Gabor Mate’s attempt to transport this plant medicine to a clinical setting with the help of Canada’s Department of National Health. Dr. Miller and his contributors explore the ongoing efforts to restore psychedelic therapies to the health field, the growing threat of overmedication by the pharmaceutical industry, and the links between psychiatric drugs and mental illness. They also discuss the newly shifting political climate and the push for new research, offering hope for an end to the War on Drugs and a potential renaissance of research into psychedelic medicines around the world.
This volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action. Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.
Aldous Huxley (1894–1963) was the author of nearly fifty books and numerous essays, best known for his dystopian novel Brave New World. Humphry Osmond (1917–2004) was a British-trained psychiatrist interested in the biological nature of mental illness and the potential for psychedelic drugs to treat psychoses, especially schizophrenia. In 1953, Huxley sent an appreciative note to Osmond about an article he and a colleague had published on their experiments with mescaline, which inspired an initial meeting and decade-long correspondence. This critical edition provides the complete Huxley-Osmond correspondence, chronicling an exchange between two brilliant thinkers who explored such subjects as psychedelics, the visionary experience, the nature of mind, human potentialities, schizophrenia, death and dying, Indigenous rituals and consciousness, socialism, capitalism, totalitarianism, power and authority, and human evolution. There are references to mutual friends, colleagues, and eminent figures of the day, as well as details about both men's personal lives. The letters bear witness to the development of mind-altering drugs aimed at discovering the mechanisms of mental illness and eventually its treatment. A detailed introduction situates the letters in their historical, social, and literary context, explores how Huxley and Osmond first coined the term "psychedelic," contextualizes their work in mid-century psychiatry, and reflects on their legacy as contributors to the science of mind-altering substances. Psychedelic Prophets is an extraordinary record of a full correspondence between two leading minds and a testament to friendship, intellectualism, empathy, and tolerance. The fact that these sentiments emerge so clearly from the letters, at a historical moment best known for polarizing ideological conflict, threats of nuclear war, and the rise of post-modernism, reveals much about the personalities of the authors and the persistence of these themes today.
Psychedelic Drug Treatments: Assisting the Therapeutic Process provides information about current and quite viable investigation into reviving and progressing with neurological research that began in the middle of the 20th century and was brought to a halt when certain drugs were banned in the 1970s. Using a question/answer format, the book will introduce you to the way in which the chemical compounds known as psychedelics affect the brain, provide you with the definitions of key terms particular to the neurological and psychological vocabulary, describe the specific disorders that can realistically be helped or relieved through treatment with psychedelics, and offer information with regard to current research being conducted in the field. This text will discuss the history of the earlier research efforts and will examine the likelihood of a resurgence of interest in the successful development of methods and practices of clinical therapy assisted by psychedelic drugs. The purpose of this volume is to promote an understanding of the use of psychedelics as tools to assist therapy and to challenge the 40-year-old prejudices against research into the possible benefits of these drugs. Features: •Questions and answers about the history, research, and treatments related to psychedelic drugs •Makes a case for the re-evaluation of psychedelics — LSD, MDMA (‘ecstasy’), DMT, psilocybin, ayahuasca, peyote, ibogaine, and more — and their clinical potential for treating a range of conditions from post-traumatic stress disorder and depression to autism and cluster headaches. •Includes numerous in-text resources such as links to Web sites, videos, articles, blogs, etc. from NIH, FDA, YouTube, and university/clinical studies
This is a different kind of book about psychedelics. Rather than describing psychedelic experiences, it presents four future-oriented ideas 'coming over the psychedelic horizon', which illustrate the potential benefits of psychedelics for humanity: * Stanislav Grof's view of our minds as a way to understand works of art (looking at Disney's Snow White). * The evidence that psychedelic-occasioned mystical experiences can boost our immune systems. * Psychedelics as a way of adding new cognitive programmes to our thinking skills. * Applying the ideas from Part 3 to learning.
Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psychological, physiological, and social problems. More than a decade ago, the U.S. government lifted its ban on all testing of psychedelic substances. Winkelman and Sessa now provide updated scientific research and applications of these substances, now moving into approved categories of medicine. The text is an up-to-date assessment of the latest advances in the field of psychedelic medicine, covering the use of LSD, psilocybin, MDMA, ayahuasca, and other substances to augment psychotherapies for a range of disorders. It discusses medical and psychiatric concerns, clinical efficacy and safety, ethical considerations, and neuroscience findings regarding the psychedelic compounds. Topics covered include an overview of psychiatric applications of psychedelics; treatments for addictions and depressive disorders; effects of psychedelics on inflammation and neuroplasticity; evidence for clinical applications of DMT, ayahuasca, and cannabidiol; psychedelic treatment of sociopathic disorders; microdosing psychedelics; training psychedelic therapists; and community-based harm reduction approaches to managing psychedelic crises.
“Cody Johnson beautifully balances historical knowledge with cutting-edge science to produce a thoroughly enjoyable and enlightening read which paints a holistic picture of the risks and benefits of psychedelic use in modern day medicine and culture.” —Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS). Magic Medicine explores the fascinating history of psychedelic substances and provides a contemporary update about their growing inclusion in modern medicine, science, and culture. Each chapter dives into the rich history of a single plant or compound and explores its therapeutic and spiritual uses in cultures near and far. Firsthand quotes allow glimmers of psychedelic light throughout. Learn all about: Classical psychedelics, including 2C-B, ayahuasca, LSD, and peyote The empathogenic psychedelics MDA and MDMA Dissociative psychedelics, including DXM, ketamine, and salvia Unique psychedelics, including cannabis, DiPT, and even fish and sea sponges The history of psychedelic plants and substances is full of colorful facts and stories, and intriguing questions. Did US Army Intelligence really use LSD as an enhanced military interrogation technique? How is DiPT able to make a familiar tune sound utterly foreign? Can MDMA (Ecstasy) help people overcome traumatic experiences? Many psychedelic plants and substances have a long history of being incorporated into various healing traditions—such as cannabis and opium in Traditional Chinese Medicine. Science is beginning to research what traditional cultures have told us for years: psychedelics have transformative healing properties. Anyone who has ever wondered about psychedelics—from complete neophytes to veteran trippers, seekers and sages to skeptics and scientists, therapists and patients to green thumbs and armchair anthropologists—will find something in this engrossing and beautifully designed book.
Recent clinical trials show that psychedelics such as LSD and psilocybin can be given safely in controlled conditions, and can cause lasting psychological benefits with one or two administrations. Supervised psychedelic sessions can reduce symptoms of anxiety, depression, and addiction, and improve well-being in healthy volunteers, for months or even years. But these benefits seem to be mediated by "mystical" experiences of cosmic consciousness, which prompts a philosophical concern: do psychedelics cause psychological benefits by inducing false or implausible beliefs about the metaphysical nature of reality? This book is the first scholarly monograph in English devoted to the philosophical analysis of psychedelic drugs. Its central focus is the apparent conflict between the growing use of psychedelics in psychiatry and the philosophical worldview of naturalism. Within the book, Letheby integrates empirical evidence and philosophical considerations in the service of a simple conclusion: this "Comforting Delusion Objection" to psychedelic therapy fails. While exotic metaphysical ideas do sometimes come up, they are not, on closer inspection, the central driver of change in psychedelic therapy. Psychedelics lead to lasting benefits by altering the sense of self, and changing how people relate to their own minds and lives-not by changing their beliefs about the ultimate nature of reality. The upshot is that a traditional conception of psychedelics as agents of insight and spirituality can be reconciled with naturalism (the philosophical position that the natural world is all there is). Controlled psychedelic use can lead to genuine forms of knowledge gain and spiritual growth-even if no Cosmic Consciousness or transcendent divine Reality exists. Philosophy of Psychedelics is an indispensable guide to the literature for researchers already engaged in the field of psychedelic psychiatry, and for researchers-especially philosophers-who want to become acquainted with this increasingly topical field.